Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MiCAN Technologies logo — "Providing high precision artificial blood cells using iPSC...

MiCAN Technologies

"Providing high precision artificial blood cells using iPSC technologies"

Founded 2016 Japan Japan 6 employees Corporate Round Total: $133.00M Health Care, Medical Devices

General Information

Company Name MiCAN Technologies
Founded Year 2016
Location Japan Japan
Employees 6
Industries Health Care, Medical Devices
Funding Stage Corporate Round
Social

BounceWatch is an independent company data service, not affiliated with MiCAN Technologies. To contact MiCAN Technologies, visit micantechnologies.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MiCAN Technologies compare?

A PDF of MiCAN Technologies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MiCAN Technologies soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MiCAN Technologies

MiCAN Technologies is a Kyoto University spinout company founded in 2016, with a focus on providing high precision artificial blood cells using iPSC technologies. The company's slogan, "Providing high precision artificial blood cells using iPSC technologies," reflects its core mission. MiCAN has developed production technologies to generate high-performance artificial blood cells from stem cells. Their Mylc cell series, particularly the cMylc kit, has garnered attention for its suitability in evaluating the efficacy of drug discovery and safety assessment, specifically in the context of COVID-19 vaccines and drug development. The company's coronavirus-optimized myeloid lineage cells are designed to serve as host cells, offering stable and robust performance for research on COVID-19. MiCAN Technologies secured a ¥128.00M Corporate Round investment on 23 August 2019, with investments from notable entities such as Osaka University Venture Capital, Graduate School of Management, and GLOBIS University. The startup operates in the Health Care industry and is headquartered in Japan.

Business keywords: stem cell technology, regenerative medicine, drug discovery, COVID-19 research, infectious diseases, immune system research, pluripotent stem cells, research tools, precision medicine, Kyoto University spinout, Mylc cell series, cMylc kit, host cell research

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate Round ¥128.00M 2
Osaka University Venture Capital
Osaka University Venture Capital, Graduate School of Management, GLOBIS University
23 Aug 2019
Convertible Note ¥5.00M 1
Graduate School of Management, GLOBIS University
20 Nov 2016

MiCAN Technologies Alternatives & Competitors

View All Alternatives
MiCAN Technologies vs
River BioMedics
River BioMedics The Netherlands

River BioMedics paves the way to the future of cardiac drug discovery

Seed
13 employees
Biotechnology, Health Care
MiCAN Technologies vs
Newcells Biotech (Axol Bioscience)
Newcells Biotech (Axol Bioscience) United Kingdom

The Newcells ophthalmology business was acquired by Axol Bioscience

12 employees
Biotechnology, Health Care
MiCAN Technologies vs
MICA Biosystems
MICA Biosystems United Kingdom

An innovative and dynamic biotech start-up, unlocking the potential of stem cells and nanotechnology...

Grant
9 employees
Biotechnology, Health Care
View all alternatives

FAQ About MiCAN Technologies

"Providing high precision artificial blood cells using iPSC technologies"
MiCAN Technologies was founded in 2016.
MiCAN Technologies is headquartered in Japan.
MiCAN Technologies operates in Health Care and Medical Devices. Its work centres on stem cell technology, regenerative medicine, drug discovery and COVID-19 research.
MiCAN Technologies has approximately 6 employees.
MiCAN Technologies has completed 2 funding rounds, raising a total of $133.00M. The latest funding stage is Corporate Round.
Top alternatives and competitors to MiCAN Technologies include River BioMedics, Newcells Biotech (Axol Bioscience), MICA Biosystems, Juventas Therapeutics, NEUROLENTECH GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MiCAN Technologies and River BioMedics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MiCAN Technologies, https://bouncewatch.com/company/mican-technologies, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes